{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:38:18Z","timestamp":1792802298165,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-07548-4","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:30:14Z","timestamp":1792740614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the gut-liver axis and gut microbiome in pediatric metabolic dysfunction\u2013associated steatotic liver disease: current evidence and future directions"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4842-7236","authenticated-orcid":false,"given":"Vybhav","family":"Venkatesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yodoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthivasan","family":"Seetharaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Anushree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"7548_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","volume":"405","author":"GBD","year":"2021","unstructured":"GBD (2021) Adolescent BMI Collaborators (2025) Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 405:785\u2013812. https:\/\/doi.org\/10.1016\/S0140-6736(25)00397-6","journal-title":"Lancet"},{"key":"7548_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s12519-024-00814-1","volume":"20","author":"EJ Lee","year":"2024","unstructured":"Lee EJ, Choi M, Ahn SB et al (2024) Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis. World J Pediatr 20:569\u2013580. https:\/\/doi.org\/10.1007\/s12519-024-00814-1","journal-title":"World J Pediatr"},{"key":"7548_CR3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186422","volume":"135","author":"JB Schwimmer","year":"2025","unstructured":"Schwimmer JB, Biddinger SB, Ibrahim SH (2025) MASLD in children: integrating epidemiological trends with mechanistic and translational advances. J Clin Invest 135. https:\/\/doi.org\/10.1172\/JCI186422","journal-title":"J Clin Invest"},{"key":"7548_CR4","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2026.02.016","volume":"84","author":"S Lefere","year":"2026","unstructured":"Lefere S, Koot BGP, Mann JP et al (2026) Update in clinical science: MASLD in children and adolescents. J Hepatol 84:1164\u20131177. https:\/\/doi.org\/10.1016\/j.jhep.2026.02.016","journal-title":"J Hepatol"},{"key":"7548_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.hbpd.2023.06.006","volume":"22","author":"M-Y Wu","year":"2023","unstructured":"Wu M-Y, Fan J-G (2023) Gut microbiome and nonalcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 22:444\u2013451. https:\/\/doi.org\/10.1016\/j.hbpd.2023.06.006","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"7548_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J, Vigliotti C, Witjes J et al (2020) Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 17:279\u2013297. https:\/\/doi.org\/10.1038\/s41575-020-0269-9","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7548_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biology11111622","volume":"11","author":"S Pezzino","year":"2022","unstructured":"Pezzino S, Sofia M, Faletra G et al (2022) Gut-liver axis and non-alcoholic fatty liver disease: a vicious circle of dysfunctions orchestrated by the gut microbiome. Biology 11. https:\/\/doi.org\/10.3390\/biology11111622","journal-title":"Biology"},{"key":"7548_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.dld.2014.02.010","volume":"46","author":"V Giorgio","year":"2014","unstructured":"Giorgio V, Miele L, Principessa L et al (2014) Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis 46:556\u2013560. https:\/\/doi.org\/10.1016\/j.dld.2014.02.010","journal-title":"Dig Liver Dis"},{"key":"7548_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep08096","volume":"5","author":"W Jiang","year":"2015","unstructured":"Jiang W, Wu N, Wang X et al (2015) Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 5. https:\/\/doi.org\/10.1038\/srep08096","journal-title":"Sci Rep"},{"key":"7548_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12070647","volume":"12","author":"H Mori","year":"2022","unstructured":"Mori H, Svegliati Baroni G, Marzioni M et al (2022) Farnesoid X receptor, bile acid metabolism, and gut microbiota. Metabolites 12. https:\/\/doi.org\/10.3390\/metabo12070647","journal-title":"Metabolites"},{"key":"7548_CR11","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","volume":"152","author":"O Ch\u00e1vez-Talavera","year":"2017","unstructured":"Ch\u00e1vez-Talavera O, Tailleux A, Lefebvre P, Staels B (2017) Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152:1679-1694.e3. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.055","journal-title":"Gastroenterology"},{"key":"7548_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/biom15040469","volume":"15","author":"E M\u00fcnte","year":"2025","unstructured":"M\u00fcnte E, Hartmann P (2025) The role of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and other metabolic diseases. Biomolecules 15:469. https:\/\/doi.org\/10.3390\/biom15040469","journal-title":"Biomolecules"},{"key":"7548_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3389\/fped.2019.00518","volume":"7","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Zhou J, Liu J et al (2019) Metagenome of gut microbiota of children with nonalcoholic fatty liver disease. Front Pediatr 7:518. https:\/\/doi.org\/10.3389\/fped.2019.00518","journal-title":"Front Pediatr"},{"key":"7548_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.01148-24","author":"L Du","year":"2025","unstructured":"Du L, Zhang K, Liang L et al (2025) Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease. mSystems. https:\/\/doi.org\/10.1128\/msystems.01148-24","journal-title":"mSystems"},{"key":"7548_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1186\/s12887-025-06144-z","volume":"25","author":"P Rohani","year":"2025","unstructured":"Rohani P, Shojaie S, Nikparast A et al (2025) The association between gut microbiota and metabolic dysfunction-associated steatotic liver disease (MASLD): a case-control study. BMC Pediatr 25:796. https:\/\/doi.org\/10.1186\/s12887-025-06144-z","journal-title":"BMC Pediatr"},{"key":"7548_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","volume":"157","author":"JB Schwimmer","year":"2019","unstructured":"Schwimmer JB, Johnson JS, Angeles JE et al (2019) Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology 157:1109\u20131122. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.028","journal-title":"Gastroenterology"},{"key":"7548_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2508951","volume":"17","author":"T Z\u00f6ggeler","year":"2025","unstructured":"Z\u00f6ggeler T, Kavallar AM, Pollio AR et al (2025) Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH. Gut Microbes 17. https:\/\/doi.org\/10.1080\/19490976.2025.2508951","journal-title":"Gut Microbes"},{"key":"7548_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/nu10111793","volume":"10","author":"M Krawczyk","year":"2018","unstructured":"Krawczyk M, Maciejewska D, Ryterska K et al (2018) Gut permeability might be improved by dietary fiber in individuals with nonalcoholic fatty liver disease (NAFLD) undergoing weight reduction. Nutrients 10. https:\/\/doi.org\/10.3390\/nu10111793","journal-title":"Nutrients"},{"key":"7548_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3945\/an.116.013151","volume":"8","author":"Z Mokhtari","year":"2017","unstructured":"Mokhtari Z, Gibson DL, Hekmatdoost A (2017) Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr 8:240\u2013252. https:\/\/doi.org\/10.3945\/an.116.013151","journal-title":"Adv Nutr"},{"key":"7548_CR20","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/HEP.0000000000001368","volume":"82","author":"SA Xanthakos","year":"2025","unstructured":"Xanthakos SA, Ibrahim SH, Adams K et al (2025) AASLD practice statement on the evaluation and management of metabolic dysfunction-associated steatotic liver disease in children. Hepatology 82:1352\u20131394. https:\/\/doi.org\/10.1097\/HEP.0000000000001368","journal-title":"Hepatology"},{"key":"7548_CR21","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1053\/j.gastro.2020.07.034","volume":"159","author":"SA Xanthakos","year":"2020","unstructured":"Xanthakos SA, Lavine JE, Yates KP et al (2020) Progression of fatty liver disease in children receiving standard of care lifestyle advice. Gastroenterology 159:1731-1751.e10. https:\/\/doi.org\/10.1053\/j.gastro.2020.07.034","journal-title":"Gastroenterology"},{"key":"7548_CR22","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1097\/HEP.0000000000001216","volume":"82","author":"KP Newton","year":"2025","unstructured":"Newton KP, Jayasekera D, Blackford AL et al (2025) Longitudinal response to standard of care in pediatric metabolic dysfunction\u2013associated steatotic liver disease: rates of improvement and worsening, and factors associated with outcomes. Hepatology 82:1198\u20131210. https:\/\/doi.org\/10.1097\/HEP.0000000000001216","journal-title":"Hepatology"},{"key":"7548_CR23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/archpediatrics.2009.93","volume":"163","author":"MB Vos","year":"2009","unstructured":"Vos MB, Weber MB, Welsh J et al (2009) Fructose and oxidized low-density lipoprotein in pediatric nonalcoholic fatty liver disease: a pilot study. Arch Pediatr Adolesc Med 163:674\u2013675. https:\/\/doi.org\/10.1001\/archpediatrics.2009.93","journal-title":"Arch Pediatr Adolesc Med"},{"key":"7548_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jama.2018.20579","volume":"321","author":"JB Schwimmer","year":"2019","unstructured":"Schwimmer JB, Ugalde-Nicalo P, Welsh JA et al (2019) Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. JAMA 321:256\u2013265. https:\/\/doi.org\/10.1001\/jama.2018.20579","journal-title":"JAMA"},{"key":"7548_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hep.22336","volume":"48","author":"V Nobili","year":"2008","unstructured":"Nobili V, Manco M, Devito R et al (2008) Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48:119\u2013128. https:\/\/doi.org\/10.1002\/hep.22336","journal-title":"Hepatology"},{"key":"7548_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/chi.2013.0022","volume":"9","author":"M Ramon-Krauel","year":"2013","unstructured":"Ramon-Krauel M, Salsberg SL, Ebbeling CB et al (2013) A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes 9:252\u2013260. https:\/\/doi.org\/10.1089\/chi.2013.0022","journal-title":"Child Obes"},{"key":"7548_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12630","volume":"15","author":"AM Goss","year":"2020","unstructured":"Goss AM, Dowla S, Pendergrass M et al (2020) Effects of a carbohydrate-restricted diet on hepatic lipid content in adolescents with non-alcoholic fatty liver disease: a pilot, randomized trial. Pediatr Obes 15. https:\/\/doi.org\/10.1111\/ijpo.12630","journal-title":"Pediatr Obes"},{"key":"7548_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/09637486.2021.1979478","volume":"73","author":"UE Akbulut","year":"2022","unstructured":"Akbulut UE, Isik IA, Atalay A et al (2022) The effect of a Mediterranean diet vs. a low-fat diet on non-alcoholic fatty liver disease in children: a randomized trial. Int J Food Sci Nutr 73:357\u2013366. https:\/\/doi.org\/10.1080\/09637486.2021.1979478","journal-title":"Int J Food Sci Nutr"},{"key":"7548_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.13163","volume":"19","author":"A Deshmukh","year":"2024","unstructured":"Deshmukh A, Sood V, Lal BB et al (2024) Effect of Indo-Mediterranean diet versus calorie-restricted diet in children with non-alcoholic fatty liver disease: a pilot randomized control trial. Pediatr Obes 19. https:\/\/doi.org\/10.1111\/ijpo.13163","journal-title":"Pediatr Obes"},{"key":"7548_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13030401","volume":"13","author":"CC Cohen","year":"2023","unstructured":"Cohen CC, Huneault H, Accardi CJ et al (2023) Metabolome \u00d7 microbiome changes associated with a diet-induced reduction in hepatic fat among adolescent boys. Metabolites 13. https:\/\/doi.org\/10.3390\/metabo13030401","journal-title":"Metabolites"},{"key":"7548_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-026-00798-5","volume":"18","author":"JW Hahn","year":"2026","unstructured":"Hahn JW, Lim JG, Lee KJ et al (2026) Clinical and microbial correlates of response to lifestyle intervention in pediatric metabolic dysfunction-associated steatotic liver disease. Gut Pathog 18. https:\/\/doi.org\/10.1186\/s13099-026-00798-5","journal-title":"Gut Pathog"},{"key":"7548_CR32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/nutrit\/nuad086","volume":"82","author":"E Amini-Salehi","year":"2024","unstructured":"Amini-Salehi E, Hassanipour S, Keivanlou M-H et al (2024) The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis. Nutr Rev 82:815\u2013830. https:\/\/doi.org\/10.1093\/nutrit\/nuad086","journal-title":"Nutr Rev"},{"key":"7548_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.nutos.2024.05.014","volume":"56","author":"J Fadhilah","year":"2024","unstructured":"Fadhilah J, Zariyah H, Pramono A et al (2024) Effect of synbiotic supplementation on liver function, metabolic profile and gut microbiota in non-alcoholic fatty liver disease (NAFLD): a meta-analysis of randomized controlled trials. Clin Nutr Open Sci 56:128\u2013151. https:\/\/doi.org\/10.1016\/j.nutos.2024.05.014","journal-title":"Clin Nutr Open Sci"},{"key":"7548_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-023-02299-x","volume":"12","author":"A Naghipour","year":"2023","unstructured":"Naghipour A, Amini-Salehi E, Orang Gorabzarmakhi M et al (2023) Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study. Syst Rev 12. https:\/\/doi.org\/10.1186\/s13643-023-02299-x","journal-title":"Syst Rev"},{"key":"7548_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41387-024-00281-7","volume":"14","author":"A Vakilpour","year":"2024","unstructured":"Vakilpour A, Amini-Salehi E, Soltani Moghadam A et al (2024) The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review. Nutr Diabetes 14. https:\/\/doi.org\/10.1038\/s41387-024-00281-7","journal-title":"Nutr Diabetes"},{"key":"7548_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.clnesp.2023.07.087","volume":"57","author":"A Mahapatro","year":"2023","unstructured":"Mahapatro A, Bawna F, Kumar V et al (2023) Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: an umbrella study on meta-analyses. Clin Nutr ESPEN 57:475\u2013486. https:\/\/doi.org\/10.1016\/j.clnesp.2023.07.087","journal-title":"Clin Nutr ESPEN"},{"key":"7548_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1638372","volume":"15","author":"X-Y Luo","year":"2025","unstructured":"Luo X-Y, Huang W-B, Lu C-H et al (2025) Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective. Front Cell Infect Microbiol 15. https:\/\/doi.org\/10.3389\/fcimb.2025.1638372","journal-title":"Front Cell Infect Microbiol"},{"key":"7548_CR38","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","volume":"31","author":"H Saeed","year":"2025","unstructured":"Saeed H, D\u00edaz LA, Gil-G\u00f3mez A et al (2025) Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 31:S94\u2013S111. https:\/\/doi.org\/10.3350\/cmh.2024.0811","journal-title":"Clin Mol Hepatol"},{"key":"7548_CR39","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/MPG.0b013e31821f9b85","volume":"52","author":"P Vajro","year":"2011","unstructured":"Vajro P, Mandato C, Licenziati MR et al (2011) Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 52:740\u2013743. https:\/\/doi.org\/10.1097\/MPG.0b013e31821f9b85","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"7548_CR40","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.12758","volume":"39","author":"A Alisi","year":"2014","unstructured":"Alisi A, Bedogni G, Baviera G et al (2014) Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 39:1276\u20131285. https:\/\/doi.org\/10.1111\/apt.12758","journal-title":"Aliment Pharmacol Ther"},{"key":"7548_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","volume":"64","author":"F Famouri","year":"2017","unstructured":"Famouri F, Shariat Z, Hashemipour M et al (2017) Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr 64:413\u2013417. https:\/\/doi.org\/10.1097\/MPG.0000000000001422","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"7548_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.5152\/tjg.2017.17084","volume":"28","author":"M \u00c7ak\u0131r","year":"2017","unstructured":"\u00c7ak\u0131r M, Aksel \u0130\u015fbilen A, Ey\u00fcpo\u011flu \u0130 et al (2017) Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease. Turk J Gastroenterol 28:377\u2013383. https:\/\/doi.org\/10.5152\/tjg.2017.17084","journal-title":"Turk J Gastroenterol"},{"key":"7548_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.47203\/IJCH.2019.v31i01.009","volume":"31","author":"P Goyal","year":"2019","unstructured":"Goyal P, Thapa BR, Sharma NR, Bhatia A (2019) Probiotic and lifestyle modification in obese pediatrics with non-alcoholic fatty liver disease. Indian J Community Health 31:50\u201356. https:\/\/doi.org\/10.47203\/IJCH.2019.v31i01.009","journal-title":"Indian J Community Health"},{"key":"7548_CR44","doi-asserted-by":"publisher","unstructured":"Poparn H, Chatrproedprai S, Treeprasertsuk S, et al (2020) Effect of synbiotic supplementation in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Med Assoc Thai 103:99\u2013104. https:\/\/doi.org\/10.35755\/jmedassocthai.2020.S08.11411","DOI":"10.35755\/jmedassocthai.2020.S08.11411"},{"key":"7548_CR45","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3345\/cep.2021.00787","volume":"65","author":"T Rodrigo","year":"2022","unstructured":"Rodrigo T, Dulani S, Nimali Seneviratne S et al (2022) Effects of probiotics combined with dietary and lifestyle modification on clinical, biochemical, and radiological parameters in obese children with nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis: a randomized clinical trial. Clin Exp Pediatr 65:304\u2013311. https:\/\/doi.org\/10.3345\/cep.2021.00787","journal-title":"Clin Exp Pediatr"},{"key":"7548_CR46","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1097\/MPG.0000000000003537","volume":"75","author":"\u039d Gkiourtzis","year":"2022","unstructured":"Gkiourtzis \u039d, Kalopitas G, Vadarlis A et al (2022) The benefit of probiotics in pediatric nonalcoholic fatty liver disease: a meta-analysis of randomized control trials. J Pediatr Gastroenterol Nutr 75:e31\u2013e37. https:\/\/doi.org\/10.1097\/MPG.0000000000003537","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"7548_CR47","doi-asserted-by":"publisher","unstructured":"Avelar-Rodr\u00edguez D, Pe\u00f1a-V\u00e9lez R, Popov J, et al (2022) Probiotics and non-alcoholic fatty liver disease in children and adolescents: a systematic review. Rev Esp Enfermedades Dig. https:\/\/doi.org\/10.17235\/reed.2022.8796\/2022","DOI":"10.17235\/reed.2022.8796\/2022"},{"key":"7548_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076123","volume":"24","author":"M Del Barrio","year":"2023","unstructured":"Del Barrio M, Lav\u00edn L, Santos-Laso \u00c1 et al (2023) Faecal microbiota transplantation, paving the way to treat non-alcoholic fatty liver disease. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24076123","journal-title":"Int J Mol Sci"},{"key":"7548_CR49","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","volume":"7","author":"D Zhou","year":"2017","unstructured":"Zhou D, Pan Q, Shen F et al (2017) Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep 7:1529. https:\/\/doi.org\/10.1038\/s41598-017-01751-y","journal-title":"Sci Rep"},{"key":"7548_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051191","volume":"10","author":"I Pinheiro","year":"2022","unstructured":"Pinheiro I, Barber\u00e1 A, Raurell I et al (2022) A nine-strain bacterial consortium improves portal hypertension and insulin signaling and delays NAFLD progression in vivo. Biomedicines 10. https:\/\/doi.org\/10.3390\/biomedicines10051191","journal-title":"Biomedicines"},{"key":"7548_CR51","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","volume":"115","author":"L Craven","year":"2020","unstructured":"Craven L, Rahman A, Nair Parvathy S et al (2020) Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol 115:1055\u20131065. https:\/\/doi.org\/10.14309\/ajg.0000000000000661","journal-title":"Am J Gastroenterol"},{"key":"7548_CR52","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/hep4.1601","volume":"4","author":"JJ Witjes","year":"2020","unstructured":"Witjes JJ, Smits LP, Pekmez CT et al (2020) Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis. Hepatol Commun 4:1578\u20131590. https:\/\/doi.org\/10.1002\/hep4.1601","journal-title":"Hepatol Commun"},{"key":"7548_CR53","doi-asserted-by":"publisher","first-page":"e46886","DOI":"10.1097\/MD.0000000000046886","volume":"105","author":"C He","year":"2026","unstructured":"He C, Zhou F, Fang X (2026) Meta-analysis of the effectiveness of fecal microbiota transplantation in the treatment of metabolic-associated fatty liver disease: a systematic review based on liver inflammation indicators and fat content. Medicine (Baltimore) 105:e46886. https:\/\/doi.org\/10.1097\/MD.0000000000046886","journal-title":"Medicine (Baltimore)"},{"key":"7548_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30415","volume":"3","author":"KSW Leong","year":"2020","unstructured":"Leong KSW, Jayasinghe TN, Wilson BC et al (2020) Effects of fecal microbiome transfer in adolescents with obesity: the gut bugs randomized controlled trial. JAMA Netw Open 3. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.30415","journal-title":"JAMA Netw Open"},{"key":"7548_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62752-4","volume":"16","author":"BC Wilson","year":"2025","unstructured":"Wilson BC, Zuppi M, Derraik JGB et al (2025) Long-term health outcomes in adolescents with obesity treated with faecal microbiota transplantation: 4-year follow-up. Nat Commun 16. https:\/\/doi.org\/10.1038\/s41467-025-62752-4","journal-title":"Nat Commun"},{"key":"7548_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11051272","volume":"11","author":"M Hsu","year":"2023","unstructured":"Hsu M, Tun KM, Batra K et al (2023) Safety and efficacy of fecal microbiota transplantation in treatment of inflammatory bowel disease in the pediatric population: a systematic review and meta-analysis. Microorganisms 11. https:\/\/doi.org\/10.3390\/microorganisms11051272","journal-title":"Microorganisms"},{"key":"7548_CR57","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.3748\/wjg.v30.i23.2964","volume":"30","author":"J Rocho\u0144","year":"2024","unstructured":"Rocho\u0144 J, Kalinowski P, Szymanek-Majchrzak K, Gr\u0105t M (2024) Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World J Gastroenterol 30:2964\u20132980. https:\/\/doi.org\/10.3748\/wjg.v30.i23.2964","journal-title":"World J Gastroenterol"},{"key":"7548_CR58","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/bcp.70487","volume":"92","author":"S Kamath","year":"2026","unstructured":"Kamath S, Chan NSL, Joyce P (2026) GLP-1 agonists and the gut microbiome: a bidirectional relationship. Br J Clin Pharmacol 92:1309\u20131325. https:\/\/doi.org\/10.1002\/bcp.70487","journal-title":"Br J Clin Pharmacol"},{"key":"7548_CR59","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","volume":"305","author":"JE Lavine","year":"2011","unstructured":"Lavine JE, Schwimmer JB, Van Natta ML et al (2011) Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305:1659\u20131668. https:\/\/doi.org\/10.1001\/jama.2011.520","journal-title":"JAMA"},{"key":"7548_CR60","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1007\/s00431-023-05169-9","volume":"182","author":"N Gkiourtzis","year":"2023","unstructured":"Gkiourtzis N, Michou P, Moutafi M et al (2023) The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Pediatr 182:4795\u20134806. https:\/\/doi.org\/10.1007\/s00431-023-05169-9","journal-title":"Eur J Pediatr"},{"key":"7548_CR61","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-1610","volume":"147","author":"R Masarwa","year":"2021","unstructured":"Masarwa R, Brunetti VC, Aloe S et al (2021) Efficacy and safety of metformin for obesity: a systematic review. Pediatrics 147. https:\/\/doi.org\/10.1542\/peds.2020-1610","journal-title":"Pediatrics"},{"key":"7548_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.13169","volume":"19","author":"G Wahi","year":"2024","unstructured":"Wahi G, St-Pierre J, Johnston BC et al (2024) Effectiveness of pharmacological interventions for managing obesity in children and adolescents: a systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline. Pediatr Obes 19. https:\/\/doi.org\/10.1111\/ijpo.13169","journal-title":"Pediatr Obes"},{"key":"7548_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111117","volume":"134","author":"B Pastor-Villaescusa","year":"2021","unstructured":"Pastor-Villaescusa B, Plaza-D\u00edaz J, Egea-Zorrilla A et al (2021) Evaluation of the gut microbiota after metformin intervention in children with obesity: a metagenomic study of a randomized controlled trial. Biomed Pharmacother 134. https:\/\/doi.org\/10.1016\/j.biopha.2020.111117","journal-title":"Biomed Pharmacother"},{"key":"7548_CR64","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","volume":"22","author":"LA Abushamat","year":"2024","unstructured":"Abushamat LA, Shah PA, Eckel RH et al (2024) The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol 22:1565\u20131574. https:\/\/doi.org\/10.1016\/j.cgh.2024.01.032","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7548_CR65","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","volume":"82","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Antunes VLJ et al (2025) Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis. Hepatology 82:1523\u20131533. https:\/\/doi.org\/10.1097\/HEP.0000000000001254","journal-title":"Hepatology"},{"key":"7548_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89408-z","volume":"15","author":"B Havranek","year":"2025","unstructured":"Havranek B, Loh R, Torre B et al (2025) Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes. Sci Rep 15. https:\/\/doi.org\/10.1038\/s41598-025-89408-z","journal-title":"Sci Rep"},{"key":"7548_CR67","unstructured":"US FDA (2025) FDA approves treatment for serious liver disease known as \u2018MASH.\u2019 FDA. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash. Accessed 11 August 2026"},{"key":"7548_CR68","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.medj.2024.03.017","volume":"5","author":"L Zhang","year":"2024","unstructured":"Zhang L, El-Shabrawi M, Baur LA et al (2024) An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease. Medicine (Baltimore) 5:797-815.e2. https:\/\/doi.org\/10.1016\/j.medj.2024.03.017","journal-title":"Medicine (Baltimore)"},{"key":"7548_CR69","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v18.i1.111211","volume":"18","author":"NB-H Ng","year":"2026","unstructured":"Ng NB-H, Sng AA, Huang JG (2026) Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: role of non-invasive diagnostics and early pharmacological intervention. World J Hepatol 18. https:\/\/doi.org\/10.4254\/wjh.v18.i1.111211","journal-title":"World J Hepatol"},{"key":"7548_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/children11030275","volume":"11","author":"E Choi","year":"2024","unstructured":"Choi E, Ramirez Tovar A, He Z et al (2024) Glucagon-like peptide-1 receptor agonists-a potential new medication for pediatric metabolic-dysfunction-associated steatotic liver disease (MASLD). Children (Basel) 11. https:\/\/doi.org\/10.3390\/children11030275","journal-title":"Children (Basel)"},{"key":"7548_CR71","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/jpn3.70242","volume":"82","author":"AM Tou","year":"2026","unstructured":"Tou AM, Panganiban J (2026) Glucagon-like peptide-1 receptor agonists in pediatric metabolic dysfunction-associated steatotic liver disease. J Pediatr Gastroenterol Nutr 82:146\u2013155. https:\/\/doi.org\/10.1002\/jpn3.70242","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"7548_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-92282-4","volume":"15","author":"T Qiu","year":"2025","unstructured":"Qiu T, Zhu X, Wu J et al (2025) Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4\/NF\u03baB pathway. Sci Rep 15. https:\/\/doi.org\/10.1038\/s41598-025-92282-4","journal-title":"Sci Rep"},{"key":"7548_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146710","volume":"26","author":"N Nishimura","year":"2025","unstructured":"Nishimura N, Kaji K, Nishimura N et al (2025) Rifaximin attenuates liver fibrosis and hepatocarcinogenesis in a rat MASH model by suppressing the gut-liver axis and epiregulin-IL-8-associated angiogenesis. Int J Mol Sci 26. https:\/\/doi.org\/10.3390\/ijms26146710","journal-title":"Int J Mol Sci"},{"key":"7548_CR74","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","volume":"30","author":"A Abdel-Razik","year":"2018","unstructured":"Abdel-Razik A, Mousa N, Shabana W et al (2018) Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. Eur J Gastroenterol Hepatol 30:1237\u20131246. https:\/\/doi.org\/10.1097\/MEG.0000000000001232","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"7548_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ph18091424","volume":"18","author":"S Fiorucci","year":"2025","unstructured":"Fiorucci S, Urbani G, Distrutti E, Biagioli M (2025) Obeticholic acid and other farnesoid-X-receptor (FXR) agonists in the treatment of liver disorders. Pharmaceuticals (Basel) 18. https:\/\/doi.org\/10.3390\/ph18091424","journal-title":"Pharmaceuticals (Basel)"},{"key":"7548_CR76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","volume":"72","author":"K Patel","year":"2020","unstructured":"Patel K, Harrison SA, Elkhashab M et al (2020) Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology 72:58\u201371. https:\/\/doi.org\/10.1002\/hep.31205","journal-title":"Hepatology"},{"key":"7548_CR77","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Lopez P, Lawitz EJ et al (2023) Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial. Nat Med 29:392\u2013400. https:\/\/doi.org\/10.1038\/s41591-022-02200-8","journal-title":"Nat Med"},{"key":"7548_CR78","doi-asserted-by":"publisher","first-page":"2650247","DOI":"10.1080\/29933935.2026.2650247","volume":"3","author":"MA Barrera-Suarez","year":"2026","unstructured":"Barrera-Suarez MA, Zhao CY, Karnatovskaia LV, Sung J (2026) Precision nutrition through diet-gut microbiome interactions: emerging insights driven by artificial intelligence, microbiome health metrics, and mechanistic modeling. Gut Microbes Reports 3:2650247. https:\/\/doi.org\/10.1080\/29933935.2026.2650247","journal-title":"Gut Microbes Reports"},{"key":"7548_CR79","doi-asserted-by":"publisher","first-page":"596","DOI":"10.4103\/ATMR.ATMR_101_25","volume":"2","author":"MM Alherfi","year":"2025","unstructured":"Alherfi MM, Khazna MS, Aldakhil AM et al (2025) Precision modulation of gut microbiome via metagenomic-driven dietary and probiotic interventions for non-alcoholic fatty liver disease management in obese Saudis. J Adv Trends Med Res 2:596\u2013601. https:\/\/doi.org\/10.4103\/ATMR.ATMR_101_25","journal-title":"J Adv Trends Med Res"},{"key":"7548_CR80","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/oby.22700","volume":"28","author":"J Ma","year":"2020","unstructured":"Ma J, Li C, Wang J, Gu J (2020) Genetically engineered Escherichia coli Nissle 1917 secreting GLP-1 analog exhibits potential antiobesity effect in high-fat diet-induced obesity mice. Obesity (Silver Spring) 28:315\u2013322. https:\/\/doi.org\/10.1002\/oby.22700","journal-title":"Obesity (Silver Spring)"},{"key":"7548_CR81","doi-asserted-by":"publisher","first-page":"15199","DOI":"10.1021\/acs.jafc.5c01674","volume":"73","author":"J Lok","year":"2025","unstructured":"Lok J, Chen C, Iannone V et al (2025) Advanced microbiome therapeutics accelerate MASLD recovery by restoring intestinal microbiota equilibrium and the gut-liver axis in a mouse model. J Agric Food Chem 73:15199\u201315214. https:\/\/doi.org\/10.1021\/acs.jafc.5c01674","journal-title":"J Agric Food Chem"},{"key":"7548_CR82","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2221485","volume":"15","author":"Y Han","year":"2023","unstructured":"Han Y, Ling Q, Wu L et al (2023) Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated \u03b3\u03b4T17 cell and macrophage polarization. Gut Microbes 15. https:\/\/doi.org\/10.1080\/19490976.2023.2221485","journal-title":"Gut Microbes"},{"key":"7548_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1123547","volume":"14","author":"J-H Shin","year":"2023","unstructured":"Shin J-H, Lee Y, Song E-J et al (2023) Faecalibacterium prausnitzii prevents hepatic damage in a mouse model of NASH induced by a high-fructose high-fat diet. Front Microbiol 14. https:\/\/doi.org\/10.3389\/fmicb.2023.1123547","journal-title":"Front Microbiol"},{"key":"7548_CR84","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3350\/cmh.2025.0475","volume":"32","author":"J Choi","year":"2026","unstructured":"Choi J, Yoon MG, Jang SH et al (2026) Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host-microbe signaling and highlights 2-hydroxyisocaproate as a potential effector. Clin Mol Hepatol 32:239\u2013257. https:\/\/doi.org\/10.3350\/cmh.2025.0475","journal-title":"Clin Mol Hepatol"},{"key":"7548_CR85","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12967-025-07478-z","volume":"24","author":"S-M Won","year":"2025","unstructured":"Won S-M, Joung H, Park IG et al (2025) The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial. J Transl Med 24:61. https:\/\/doi.org\/10.1186\/s12967-025-07478-z","journal-title":"J Transl Med"},{"key":"7548_CR86","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1038\/s41467-023-39028-w","volume":"14","author":"L Gan","year":"2023","unstructured":"Gan L, Feng Y, Du B et al (2023) Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat Commun 14:3215. https:\/\/doi.org\/10.1038\/s41467-023-39028-w","journal-title":"Nat Commun"},{"key":"7548_CR87","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1056\/NEJMoa1813909","volume":"380","author":"TH Inge","year":"2019","unstructured":"Inge TH, Courcoulas AP, Jenkins TM et al (2019) Five-year outcomes of gastric bypass in adolescents as compared with adults. N Engl J Med 380:2136\u20132145. https:\/\/doi.org\/10.1056\/NEJMoa1813909","journal-title":"N Engl J Med"},{"key":"7548_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2467833","volume":"17","author":"CO Akagbosu","year":"2025","unstructured":"Akagbosu CO, McCauley KE, Namasivayam S et al (2025) Gut microbiome shifts in adolescents after sleeve gastrectomy with increased oral-associated taxa and pro-inflammatory potential. Gut Microbes 17. https:\/\/doi.org\/10.1080\/19490976.2025.2467833","journal-title":"Gut Microbes"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07548-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07548-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07548-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:02:48Z","timestamp":1792800168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07548-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":88,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7548"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07548-4","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"878"}}